Icon showing Nucala (mepolizumab) to be the number one prescribed anti-IL-5
Patient with hypereosinophilic syndrome (HES) with the NUCALA logo over one eye

BATTLE TESTED

With proven protection from flares in HES and an established safety profile—make NUCALA your first-choice biologic

SEE NUCALA EFFICACY DATA

*IQVIA National Prescription Audit from January 2023 to December 2023 for all indications combined.

NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

Learn more about the established safety profile of NUCALA in HES.

Choose NUCALA for HES

PROVEN PROTECTION FROM FLARES IN A RANDOMIZED, PLACEBO-CONTROLLED TRIAL1

Infographic stating 72 percent of patients had zero flares vs 44% with placebo

Results are descriptive.

Primary endpoint results: Proportion of patients who experienced HES flare(s)† during the 32-week study or withdrew. NUCALA 28% vs placebo 56%, P=0.002.

†HES flare: Worsening of clinical signs/symptoms or increased eosinophils (on ≥2 occasions), resulting in an escalation/addition of oral corticosteroids (OCS) or cytotoxic or immunosuppressive therapy.

Pivotal study design

NUCALA for HES: what you need to know

Learn about HES

IDENTIFYING HES

The definition, clinical manifestations, and more

LEARN ABOUT HES

Flare reduction data

FLARE DATA

Proportion of patients with flares and time to first flare.

REVIEW THE DATA

Decreased blood eosinophils

EOSINOPHIL REDUCTION AND MECHANISM OF ACTION

See the results of NUCALA on eosinophil reduction.

VIEW EOSINOPHIL DATA AND MOA

Request a rep

Want to know more?

Request a rep

NUCALA access and support enrollment

GATEWAY TO NUCALA ENROLLMENT FORM

For biologic coordinators and other HCPs who help patients manage their NUCALA injection therapy: get resources right now to help them start and stay on NUCALA.

GO TO ACCESS & SUPPORT

NUCALA once-monthly dosing

ONCE-MONTHLY DOSING

Fixed dosing, independent of weight. See all the options for at-home or in-office administration. Watch “how-to” videos and download the full Instructions for Use.

‡Every 4 weeks.

GET DOSING DETAILS

Red blood eosinophils to represent NUCALA as targeted therapy for 4 eosinophil-driven diseases

NUCALA is the TARGETED THERAPY for 4 eosinophil-driven diseases

NUCALA is the #1 prescribed anti-IL-5.* It is indicated for SEA, CRSwNP, EGPA, or HES.

EXPLORE INDICATIONS

*IQVIA National Prescription Audit from January 2023 to December 2023 for all indications combined.